Mifepristone provides clear QOL benefit in uterine leiomyoma

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.519, 2007-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Surgical treatment for uterine leiomyoma costly

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 566, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Treatment of symptomatic uterine leiomyoma with letrozole

By Gurates Bilgin Parmaksiz Cem Kilic Gokhan Celik Husnu Kumru Selahattin Simsek Mehmet

Reproductive BioMedicine Online, Vol. 17, Iss. 4, 2008-10 ,pp. : 569-574

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Thyroxine plus liothyronine: no QOL benefit

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 439, 2003-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

No long-term QOL benefit for CRT

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 637, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Ranolazine provides sustained improvements in health status and QOL

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 551, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite